ESC Professional Premium Access

Pericardial disease, myocardial disease, COVID-19

Event: ESC Congress 2022
Topic: Valvular Heart Disease
Session type: Moderated ePosters
Date: 29 August 2022
Time: 14:15 - 14:45

Congress Session

6 presentations in this session

Risk of acute myocardial infarction, stroke and thromboembolism following COVID-19 vaccination compared to testing positive for COVID-19 infection: a nationwide cohort study of 4.6 mio individuals

Speaker: Mr M. Lassen (Copenhagen, DK)

Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants

Speaker: Doctor E. Kulikowski (Calgary, CA)

No cardiac sequelae after COVID-19: results of the one year follow-up with echocardiography and biomarkers

Speaker: Doctor M. Radvan (Brno, CZ)

PTX3 as a novel inflammatory biomarker in patients with myocarditis

Speaker: Doctor A. Villatore (Milan, IT)

Clinical outcome of patients with severe malignant pericardial effusion due to neoplastic disease undergoing percutaneous balloon pericardiotomy during COVID-19 pandemic

Speaker: Doctor E. Alfonso Rodriguez (Havana, CU)

The burden of coronary revascularization associated with lipoprotein(a) in patients with atherosclerotic cardiovascular disease: data from the UK Biobank

Speaker: Doctor P. Welsh (Glasgow, GB)

6 speakers from this session

Mr Mats Christian Hoejbjerg Lassen

Gentofte University Hospital, Copenhagen (Denmark)
1 follower

Doctor Ewelina Kulikowski

Resverlogix Corp, Calgary (Canada)
1 presentation
0 follower

Doctor Martin Radvan

FNUSA, Brno (Czechia)
0 follower

Doctor Andrea Villatore

University Vita-Salute San Raffaele, Milan (Italy)
1 follower

Doctor Emilio Alfonso Rodriguez

Institute of Cardiology and Cardiovascular Surgery, Havana (Cuba)
1 follower

Doctor Paul Welsh

Cardiovascular Research Centre of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
0 follower

This platform is supported by

logo Novo Nordisk